Global strategies for the treatment of early-stage and advanced cervical cancer

被引:86
作者
Duenas-Gonzalez, Alfonso [1 ]
Campbell, Sergio [2 ]
机构
[1] Inst Nacl Cancerol, Inst Invest Biomed UNAM, San Fernando 22, Mexico City 14080, DF, Mexico
[2] Unidad Med Familiar IMSS, 53 Zapopan Jalisco, Zapopan, Mexico
关键词
cervical cancer; chemoradiation; gene targetable alterations; immunotherapy; less radical surgery; molecular-targeted therapy; SPARING RADICAL HYSTERECTOMY; SQUAMOUS-CELL CARCINOMA; IMPROVED SURVIVAL; PHASE-I; CISPLATIN; RADIOTHERAPY; RADIATION; RECURRENT; BEVACIZUMAB; THERAPY;
D O I
10.1097/GCO.0000000000000234
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review Recent peer-reviewed publications on the treatment of early, locally advanced and advanced cervical cancer patients are reviewed to gain insight into the main research done in the field. Recent findings In early-stage patients where cure is offered to most patients, research focuses on more conservative or less morbid approaches to increase quality of life and reduce the treatment-related sexual dysfunction. No major advances have occurred for treating locally advanced disease since the introduction of concurrent chemoradiation, but efforts are directed to increase efficacy while reducing toxicity with the use of combination chemoradiation and modern radiation technologies. Molecular-targeted therapy and identification of targetable gene alterations as well as immunotherapy are actively pursued in patients with advanced disease. Summary Although global statistics indicate a trend for decreased age-standardized incidence rates, social and economical factors impede the uptake of therapeutic advances achieved as many patients have no access even to basic resources for treating cancer. The adherence to quality indicators in delivery of optimized standard concurrent chemoradiation and adherence to guidelines in cervical cancer surgery must not be underestimated. Major efforts are needed in both the scientific and social aspects of cervical cancer treatment to reduce mortality.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 44 条
  • [1] Is extended-field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?
    Al Asiri, Mushabbab
    Tunio, Mutahir A.
    Mohamed, Reham
    Bayoumi, Yasser
    Alhadab, Abdulrehman
    Saleh, Rasha M.
    AlArifi, Muhannad Saud
    Alobaid, Abdelaziz
    [J]. CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 339 - 348
  • [2] [Anonymous], 2014, Cancer Discov, V4, pOF2, DOI 10.1158/2159-8290.CD-NB2014-010
  • [3] [Anonymous], COCHRANE DATABASE SY
  • [4] Bae H, 2015, SUPPORT CARE CANC
  • [5] Relationship Between Low Hemoglobin Levels and Outcomes After Treatment With Radiation or Chemoradiation in Patients With Cervical Cancer: Has the Impact of Anemia Been Overstated?
    Bishop, Andrew J.
    Allen, Pamela K.
    Klopp, Ann H.
    Meyer, Larissa A.
    Eifel, Patricia J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (01): : 196 - 205
  • [6] Radical Surgery in Patients With Residual Disease After (Chemo) Radiation for Cervical Cancer
    Boers, Aniek
    Arts, Henriette J. G.
    Klip, Harry
    Nijhuis, Esther R.
    Pras, Elisabeth
    Hollema, Harry
    Wisman, G. Bea A.
    Nijman, Hans W.
    Mourits, Marian J. E.
    Reyners, Anna K. L.
    de Bock, Geertruida H.
    Thomas, Gillian
    van der Zee, Ate G. J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (07) : 1276 - 1285
  • [7] Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma
    Burotto, Mauricio
    Edgerly, Maureen
    Poruchynsky, Marianne
    Velarde, Margarita
    Wilkerson, Julia
    Kotz, Herb
    Bates, Susan
    Balasubramaniam, Sanjeeve
    Fojo, Tito
    [J]. ONCOLOGIST, 2015, 20 (07) : 725 - 726
  • [8] Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers
    Chantalat, Elodie
    Vidal, Fabien
    Leguevaque, Pierre
    Lepage, Benoit
    Mathevet, Patrice
    Deslandres, Marion
    Motton, Stephanie
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 193 : 118 - 122
  • [9] Correa CS, 2015, ARCH GYNECOL OBSTET
  • [10] PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
    de la Rochefordiere, Anne
    Kamal, Maud
    Floquet, Anne
    Thomas, Laurence
    Petrow, Peter
    Petit, Thierry
    Pop, Marius
    Fabbro, Michel
    Kerr, Christine
    Joly, Florence
    Sevin, Emmanuel
    Maillard, Sophie
    Cure, Herve
    Weber, Beatrice
    Brunaud, Claire
    Minsat, Mathieu
    Gonzague, Laurence
    Berton-Rigaud, Dominique
    Aumont, Maud
    Gladieff, Laurence
    Peignaux, Karine
    Bernard, Virginie
    Leroy, Quentin
    Bieche, Ivan
    Margogne, Audrey
    Nadan, AnaTereza
    Fourchotte, Virginie
    Diallo, Alhassane
    Asselain, Benard
    Plancher, Corine
    Armanet, Sebastien
    Beuzeboc, Philippe
    Scholl, Suzy M.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2530 - 2537